(Q37262366)

19 August 2017

Gene expression profiling of plasma cells at myeloma relapse from tandem transplantation trial Total Therapy 2 predicts subsequent survival (English)

1 reference

19 August 2017

6

Frits van Rhee

0 references

Bart Barlogie

14

object named as

Bart Barlogie

1 reference

19 August 2017

9

Sarah Waheed

1 reference

19 August 2017

13

Antje Hoering

1 reference

19 August 2017

7

Elias Anaissie

1 reference

19 August 2017

Bijay Nair

1

1 reference

19 August 2017

John D Shaughnessy

2

1 reference

19 August 2017

Yiming Zhou

3

1 reference

19 August 2017

Marie Astrid-Cartron

4

1 reference

19 August 2017

Pingping Qu

5

1 reference

19 August 2017

Yazan Alsayed

8

1 reference

19 August 2017

Klaus Hollmig

10

1 reference

19 August 2017

Jackie Szymonifka

11

1 reference

19 August 2017

Nathan Petty

12

1 reference

19 August 2017

language of work or name

English

0 references

publication date

23 April 2009

1 reference

19 August 2017

4

1 reference

based on heuristic

inferred from page(s)

published in

Blood

1 reference

19 August 2017

113

1 reference

19 August 2017

26

1 reference

19 August 2017

6572-6575

1 reference

Thalidomide arm of Total Therapy 2 improves complete remission duration and survival in myeloma patients with metaphase cytogenetic abnormalities

19 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2710916

An analysis of the clinical and biologic significance of TP53 loss and the identification of potential novel transcriptional targets of TP53 in multiple myeloma

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2710916

The molecular classification of multiple myeloma

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2710916

Prognostic and therapeutic significance of myeloma genetics and gene expression profiling.

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2710916

Prolonged Disease-Free Survival in Hodgkin's Disease with MOPP Reinduction After First Relapse

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2710916

High-risk myeloma: a gene expression based risk-stratification model for newly diagnosed multiple myeloma treated with high-dose therapy is predictive of outcome in relapsed disease treated with single-agent bortezomib or high-dose dexamethasone.

26 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2710916

Gene expression profiling and correlation with outcome in clinical trials of the proteasome inhibitor bortezomib

3 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2710916

A validated gene expression model of high-risk multiple myeloma is defined by deregulated expression of genes mapping to chromosome 1.

3 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2710916

Thalidomide and hematopoietic-cell transplantation for multiple myeloma

3 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2710916

10.1182/BLOOD-2009-02-207803

3 September 2018

Identifiers

DOI

1 reference

19 August 2017

1 reference

19 August 2017

PubMed publication ID

19389881

1 reference